wersja polska  
Mediton - Publishing House
Start page  Journals  Books  Conferences  News  Mediton  Contact   
print this
   Allergy Asthma Immunology - archive  

Allergy Asthma Immunology
     Editorial staff
     Editorial board
     For authors
Allergology Review

 Search in articles:
  Authority of Polish Society of Allergology

vol 12. no 3. September 2007  

 Bronchial asthma
Safety and efficacy of long-acting beta-agonists

Rising asthma morbidity rates and often insufficient control of the disease achievable by means of currently available methods make it necessary to find new, safe and efficient therapeutic options. Long-acting beta-agonists have well-documented effect on the bronchoconstriction component of the asthma, but they lack the anti-inflammatory effect. Thus, they should not be used as the first line therapy in asthma treatment. The available data suggest that in patients whose asthma is not sufficiently controlled by means of anti-inflammatory drugs alone, the addition of LABA may bring good results. At the same time it has been stressed that the antiasthmatic therapy should be individualized and take into consideration all coexisting factors and individual patients’ response to the therapy. The aim of this review article is presentation of current results of the research on the mechanism of action of long-acting beta-agonists and the objective evaluation of their safety and efficacy.

keywords: astma, długo działające ?2-mimetyki, receptor ?2-adrenergiczny, synergizm, desensytyzacja, asthma, long-acting ?2-agonists, ?2-adrenergic receptor, synergy, desensitization

pages: from 142 to 154

estimated time of download (365 kB)
broadband speed:561282565121024[kbps]

You need to have Adobe Acrobat Reader to view the PDF file. It's free. If you don't have the Adobe Acrobat Reader plugin yet, you can get it HERE.

Start page | Journals | Books | Conferences | News | Mediton | Contact

Copyright © 1996-2020 Mediton Publishing House | All rights reserved.